CNBC's Jim Cramer on Thursday recommended the stock of Amwell as a buy, but advised investors wait on the share price to come down before starting a position. Amwell, a telemedicine supplier that began trading on the New York Stock Exchange this afternoon, closed at $23.07 a share in its first day on the public